Last reviewed · How we verify
Dimolegin 40 mg
At a glance
| Generic name | Dimolegin 40 mg |
|---|---|
| Also known as | DD217 |
| Sponsor | PharmaDiall Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement (PHASE2)
- Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19 (PHASE3)
- A Study of Pharmacokinetics, Safety and Tolerability of Dimolegin (DD217) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dimolegin 40 mg CI brief — competitive landscape report
- Dimolegin 40 mg updates RSS · CI watch RSS
- PharmaDiall Ltd. portfolio CI